

July 12, 2024

News Release

Company: Olympus Corporation  
Stefan Kaufmann, Director, Representative Executive Officer, President and CEO  
(Code: 7733, Prime, Tokyo Stock Exchange)  
Contact: Takaaki Sakurai, Vice President, Investor Relations  
TEL: +81-42-642-2111

### **(Progress of disclosure matters) Notice Concerning Transfer of Orthopedic Business**

Olympus Corporation ("Olympus") hereby announces that Olympus and its related companies (collectively "Olympus Group") have completed the transfer of our group's Orthopedic Business on July 12, 2024. The transaction was originally announced in the "Notice Concerning Transfer of Orthopedic Business" dated May 27, 2024.

#### 1. Overview

Olympus Group has transferred all shares of its subsidiaries Olympus Terumo Biomaterials Corporation and FH Ortho SAS, to PTCJ-6O Holdings Inc. and PTCJ-6F Holdings Inc., both of which were established by Polaris Capital Group Co., Ltd. for the purpose of purchasing our group's Orthopedic Business (the "Transfer").

For details regarding the Transfer, please refer to the "Notice Concerning Transfer of Orthopedic Business" which Olympus disclosed on May 27, 2024.

#### 2. Date of commencement of the Transfer

July 12, 2024

#### 3. The transfer price

As announced in the timely disclosure dated May 27, 2024, the transfer price was fixed at the time of the share transfer.

Although the transfer price is not disclosed due to the confidentiality obligations under the share purchase agreement, the price was comprehensively determined based on negotiations with the counterparty in a fair process, recent financial results and management conditions of the target companies, as well as earnings estimates, etc., and thus is recognized as a fair price.

#### 4. Contemplated number of shares transferred, transfer price, and shareholding before and after the Transfer

##### (1) Olympus Terumo Biomaterials Corporation

(i)	Number of shares held before the change	200,649 shares (Ratio of voting rights held: 100.0 %)
(ii)	Number of shares to be transferred	200,649 shares

(iii)	Number of shares held after the change	0 shares (Ratio of voting rights held: 0.0 %)
-------	--	---

(2) FH Ortho SAS

(i)	Number of shares held before the change	60,422,415 shares (Ratio of voting rights held: 100.0 %)
(ii)	Number of shares to be transferred	60,422,415 shares
(iii)	Number of shares held after the change	0 shares (Ratio of voting rights held: 0.0 %)

5. Future outlook

We expect that the impact on our consolidated operating profit for the fiscal year ending March 31, 2025 will be immaterial. We will promptly announce any events that should be disclosed in the future.